TNDM Tandem Diabetes Care
- 36.200
- -0.490-1.34%
- 36.050
- -0.150-0.41%
Tandem Diabetes Care News
Wells Fargo: Upgraded the Tandem Diabetes Care (TNDM.US) rating from a wait-and-see shareholding rating to an increase in holdings rating, and the target price was adjusted from $21.00 to $45.00.
Tandem Diabetes Care Analyst Ratings
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target Is $45
Leerink Partners: Upgraded the Tandem Diabetes Care (TNDM.US) rating from the market unanimously to superior to the market rating, and the target price was adjusted from $34.00 to $45.00.
Tandem Diabetes Care Analyst Ratings
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target Is $45
Tandem Diabetes Care Analyst Ratings
Tandem Diabetes Care Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Tandem Diabetes Care (TNDM), Apyx Medical (APYX)
Tandem Diabetes Care Analyst Ratings
Stifel Upgrades Tandem Diabetes Care to Buy, Announces $37 Price Target
Tandem Diabetes Care Analyst Ratings
Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $31
Tandem Diabetes Care (TNDM) Gets a Buy From Lake Street
Craig-Hallum Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Tandem Diabetes Care Holds Steady: A Cautious Outlook Amidst Growth and Competitive Uncertainty
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tandem Diabetes Care (TNDM)
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Harmony Biosciences Holdings (HRMY) and Tandem Diabetes Care (TNDM)
Piper Sandler Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)
Tandem Diabetes Care: Steady Growth Prospects and Hold Rating Amid Market Challenges
Analysis
Price Target
No Data
